What is Integrated Cellular and Molecular Diagnostics?
Integrated Cellular and Molecular Diagnostics operates as a premier anatomic and clinical pathology laboratory, maintaining rigorous accreditation from the College of American Pathologists. The company serves as a critical infrastructure partner for local hospitals, physician groups, and surgery centers, providing high-efficiency diagnostic and prognostic support. By integrating advanced molecular technologies with traditional pathology, the firm addresses the dual mandate of improving patient outcomes while simultaneously driving down systemic healthcare costs. Their business model centers on providing a universal diagnostic source, effectively streamlining laboratory management for healthcare providers who require immediate, reliable, and high-quality data to inform clinical decision-making.
How much funding has Integrated Cellular and Molecular Diagnostics raised?
Integrated Cellular and Molecular Diagnostics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Integrated Cellular and Molecular Diagnostics
PPP
Public-Private Partnership
What's next for Integrated Cellular and Molecular Diagnostics?
With the infusion of this latest capital, Integrated Cellular and Molecular Diagnostics is poised to scale its laboratory management solutions and expand its technological capabilities. The company's trajectory suggests a focus on deepening its integration with existing hospital networks and potentially scaling its diagnostic throughput to meet the rising demand for precision medicine. As the firm moves through this late-stage growth phase, the strategic deployment of these funds will likely prioritize the adoption of next-generation sequencing and automated diagnostic workflows. This evolution is expected to solidify the company's role as a cornerstone of modern diagnostic infrastructure, ensuring that it remains at the forefront of clinical pathology innovation while maintaining the operational efficiency required to navigate the complexities of the current healthcare reimbursement environment.
See full Integrated Cellular and Molecular Diagnostics company page
